{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:28:05Z","timestamp":1768699685098,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1124\/dmd.121.000369","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T20:10:13Z","timestamp":1627330213000},"page":"892-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4\/5 Possibly via Heme Destruction by Ketene Intermediate"],"prefix":"10.1016","volume":"49","author":[{"given":"Chen","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000369_bib1","first-page":"443","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective","volume":"43","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000369_bib2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/tx020052x","article-title":"Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein","volume":"15","author":"Blobaum","year":"2002","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000369_bib3","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1517\/14656566.2010.481283","article-title":"Gefitinib for the treatment of non-small-cell lung cancer","volume":"11","author":"Campbell","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/dmd.121.000369_bib4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/17425255.2015.1034688","article-title":"Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors\/inducers using physiologically based pharmacokinetic modeling","volume":"11","author":"Chen","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000369_bib5","first-page":"2958","article-title":"A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.121.000369_bib6","unstructured":"Food and Drug Administration (2020) In Vitro Drug Interaction Studies: Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. Guidance for Industry. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD. Available from https:\/\/www.fda.gov\/media\/134582\/download"},{"key":"10.1124\/dmd.121.000369_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bcp.2015.07.036","article-title":"Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A","volume":"97","author":"Foo","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000369_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/tx7002504","article-title":"Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications","volume":"21","author":"Hollenberg","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000369_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/dmd.105.006874","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition","volume":"34","author":"Galetin","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000369_bib10","first-page":"1301","article-title":"Erlotinib in the treatment of non-small cell lung cancer: current status and future developments","volume":"30","author":"Gridelli","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1124\/dmd.121.000369_bib11","first-page":"90","article-title":"Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer","volume":"25","author":"Gu","year":"2013","journal-title":"Chin J Cancer Res"},{"key":"10.1124\/dmd.121.000369_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138920007780866807","article-title":"Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions","volume":"8","author":"Kalgutkar","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000369_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000369_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","article-title":"Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000369_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1389200013338478","article-title":"Mechanism-based inactivators as probes of cytochrome P450 structure and function","volume":"2","author":"Kent","year":"2001","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000369_bib16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1124\/dmd.104.003475","article-title":"Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes","volume":"33","author":"Lim","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000369_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1124\/jpet.301.1.160","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein","volume":"301","author":"Lin","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000369_bib18","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/rcm.5061","article-title":"Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography\/quadrupole time-of-flight tandem mass spectrometry","volume":"25","author":"Liu","year":"2011","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/dmd.121.000369_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.lungcan.2015.05.024","article-title":"Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer","volume":"89","author":"Liu","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1124\/dmd.121.000369_bib20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/dmd.117.079780","article-title":"Nitidine chloride is a mechanism-based inactivator of CYP2D6","volume":"46","author":"Mao","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000369_bib21","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1021\/ja01076a028","article-title":"Strained ring systems. I. Peroxidation studies with certain acetylenes. The relevance of oxirene intermediates","volume":"86","author":"McDonald","year":"1964","journal-title":"J Am Chem Soc"},{"key":"10.1124\/dmd.121.000369_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2019.04.005","article-title":"Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: potent inhibition by azelnidipine and manidipine","volume":"306","author":"Ikemura","year":"2019","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.121.000369_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clpt.2005.09.004","article-title":"In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach","volume":"78","author":"Obach","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000369_bib24","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm300065h","article-title":"Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks","volume":"55","author":"Orr","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.121.000369_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1021\/tx00009a001","article-title":"Covalent bonding of the prosthetic heme to protein: a potential mechanism for the suicide inactivation or activation of hemoproteins","volume":"2","author":"Osawa","year":"1989","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000369_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.critrevonc.2011.11.010","article-title":"Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence","volume":"83","author":"Ou","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1124\/dmd.121.000369_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-395706-1.50007-8","article-title":"Hard and soft acids and bases","volume":"5","author":"Pearson","year":"1969","journal-title":"Surv Progr Chem"},{"key":"10.1124\/dmd.121.000369_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/tx990195s","article-title":"Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry","volume":"13","author":"Regal","year":"2000","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000369_bib29","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00228-012-1288-4","article-title":"Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers","volume":"68","author":"Ruan","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000369_bib30","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.121.000369_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0076-6879(95)49038-8","article-title":"Mechanism-based enzyme inactivators","volume":"249","author":"Silverman","year":"1995","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.121.000369_bib32","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000369_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","article-title":"Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies","volume":"76","author":"Tan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1124\/dmd.121.000369_bib34","first-page":"1691","article-title":"Pharmacology and clinical evaluation of icotinib hydrochloride","volume":"18","author":"Tan","year":"2009","journal-title":"Zhongguo Xin Yao Zazhi"},{"key":"10.1124\/dmd.121.000369_bib35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000369_bib36","doi-asserted-by":"crossref","first-page":"10755","DOI":"10.1021\/ac502796x","article-title":"Selective and sensitive platform for function-based screening of potentially harmful furans","volume":"86","author":"Wang","year":"2014","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.121.000369_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.21037\/tcr.2017.01.36","article-title":"Zoledronic acid as potential efficacy application combined with icotinib for non-small cell lung cancer with bone metastases","volume":"6","author":"Wang","year":"2017","journal-title":"Transl Cancer Res"},{"key":"10.1124\/dmd.121.000369_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00002018-200326060-00004","article-title":"Potentially significant drug interactions of class III antiarrhythmic drugs","volume":"26","author":"Yamreudeewong","year":"2003","journal-title":"Drug Saf"},{"key":"10.1124\/dmd.121.000369_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3892\/ol.2013.1657","article-title":"Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer: a case report","volume":"7","author":"Zhao","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1124\/dmd.121.000369_bib41","first-page":"2244","article-title":"Feiliu decoction combined with icotinib tablets in the treatment of advanced lung cancer 30 cases","volume":"32","author":"Zhao","year":"2017","journal-title":"Guangming J Chin Med"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:49:39Z","timestamp":1740055779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0090955624079480"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000369","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4\/5 Possibly via Heme Destruction by Ketene Intermediate","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}